Aminocandin

Summary

Aminocandin is an investigational echinocandin antifungal administered intravenously. It targets the fungal cell‑wall enzyme β‑1,3‑D‑glucan synthase, impairing cell‑wall synthesis in Candida and Aspergillus species. Pre‑clinical studies show activity against both drug‑susceptible and resistant isolates, and laboratory work suggests synergy with the antibiotic colistin.

Mechanism of Action

Aminocandin belongs to the cyclic lipopeptide echinocandins and inhibits the enzyme 1,3‑β‑D‑glucan synthase, which is essential for constructing the β‑glucan polymer of the fungal cell wall. Inhibition weakens the wall, leading to osmotic instability and cell death. In combination studies, the weakened wall allows colistin to more readily disrupt the fungal plasma membrane, enhancing overall antifungal activity.

What the Research Shows

Animal models provide the bulk of evidence for aminocandin. In neutropenic mice with disseminated Aspergillus fumigatus infection, intravenous doses of 1–5 mg/kg improved survival and reduced organ fungal burden, outperforming amphotericin B and itraconazole in some strains, including itraconazole‑resistant isolates. In murine Candida glabrata infection, aminocandin was more potent than caspofungin against isolates with reduced caspofungin susceptibility, though higher single doses (≥10 mg/kg) were needed. In vitro screens identified colistin as a synergistic partner, increasing membrane permeabilization of Candida albicans when combined with aminocandin. No human clinical trials have been reported; data are limited to in‑vitro assays and rodent infection models.

Reported Benefits

Pre‑clinical data indicate a broad spectrum covering Candida spp. (including C. glabrata) and Aspergillus spp., with activity against strains resistant to itraconazole or caspofungin. In mouse models, aminocandin achieved 100 % survival at certain doses and demonstrated fungicidal activity, sterilising a proportion of organs. The drug’s extended half‑life in animals suggests the potential for less‑frequent dosing, and synergy with colistin may offer a strategy for refractory infections.

Limitations of the Evidence

Evidence is confined to laboratory and animal studies; no human efficacy or safety data exist. Effective dosing against resistant isolates appears higher than for susceptible strains, and the optimal dosing schedule is undefined. The requirement for intravenous administration may limit outpatient use. Potential drug interactions and tolerability in patients remain unknown until clinical trials are conducted.

Safety Considerations

Published abstracts report no adverse events in animal studies, but human safety information is absent. As an echinocandin, aminocandin is presumed to share the class’s generally favorable safety profile, yet without clinical data the incidence of hepatotoxicity, infusion reactions, or other toxicities cannot be confirmed. Caution is warranted until human trials establish a safety record.

How It Is Administered

Aminocandin is formulated for intravenous infusion only. Pre‑clinical pharmacokinetic work suggests a prolonged half‑life that could allow dosing intervals longer than once daily, but the exact regimen has not been defined in humans.

Routes of Administration

Goals & Uses

• Treatment of invasive aspergillosisAntifungalLow
• Treatment of invasive candidiasisAntifungalModerate
• Invasive aspergillosisAntifungalLow
• Treatment of Pneumocystis pneumoniaAntifungalLow
• Invasive candidiasisAntifungalModerate

Contraindications

• Hypersensitivity to echinocandinsAllergyHigh
• Hypersensitivity to aminocandin or echinocandinsAllergyHigh
• Known hypersensitivity to echinocandinsAllergyHigh

Adverse Effects

• Elevated hepatic transaminasesLiverUncommon
• HeadacheNeurologicCommonPain in the head or upper neck
• HypotensionCardiovascularRareLow blood pressure
• Infusion‑related reactionsGeneralCommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Elevated liver enzymesHepaticUncommonIncrease in AST/ALT or other hepatic markers
• Infusion-related reactionsHypersensitivityCommon

Drug Interactions

• Cytochrome P450 substratesLow
• CyclosporineModerate
• TacrolimusLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Pediatric patientsAgeRelative
• Severe hepatic impairmentOrgan ImpairmentRelative
• Severe hepatic impairment (Child‑Pugh C)Liver DiseaseRelative

Regulatory Status

• European UnionInvestigationalUnder EMA review; not marketed.
• United StatesInvestigationalPhase II trials completed; not FDA‑approved.
• United KingdomUnknownNo MHRA approval; status post-Brexit unclear but presumed unapproved

Never received regulatory approval in any major jurisdiction. Phase II clinical trials were conducted but development was discontinued. Not approved by FDA, EMA, or MHRA.

Evidence & Sources

• Synergy of the antibiotic colistin with echinocandin antifungals in Candida species
  Journal ArticleLowZeidler U, et al.2013-01-01T00:00:00.000000Z
• Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus
  Journal ArticleLowWarn PA, et al.2010-01-01T00:00:00.000000Z
• Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility
  Journal ArticleLowBrzankalski GE, et al.2008-01-01T00:00:00.000000Z
• Newer antifungal agents
  Journal ArticleModerateTürel O2011-01-01T00:00:00.000000Z
• New and emerging treatments for fungal infections
  Journal ArticleModeratePasqualotto AC, Denning DW2008-01-01T00:00:00.000000Z
• Emerging echinocandins for treatment of invasive fungal infections
  Journal ArticleModerateTurner MS, Drew RH, Perfect JR2006-01-01T00:00:00.000000Z

Frequently Asked Questions